NEONC TECHNOLOGIES HOLDINGS, INC. NTHI

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain- malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.

Last close 3.27 2026-10-23
Market cap $84.8M 2026-06-30 share count
52-week range 2.50 - 12.00

Valuation FY2025 figures against the last close

P/S2,120.8x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.20

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
Revenue $40.0K$83.0K—
R&D $3.6M$3.0M—
SG&A $4.8M$1.7M—
Total operating expenses $58.3M$7.2M—
Operating income -$58.2M-$7.1M—
Interest expense $2.5M$2.6M—
Net income -$62.1M-$11.9M—
EPS, basic -3.20-0.69—
EPS, diluted -3.20-0.69—
Shares, diluted (wtd. avg.) 19.4M17.3M—

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $58.7K$64.9K$31.9K
Total current assets $1.4M$2.2M—
Total assets $2.8M$3.4M—
Accounts payable $6.1M$2.9M—
Total current liabilities $20.0M$8.9M—
Total liabilities $20.3M$8.9M—
Retained earnings -$112.8M-$50.6M—
Total equity -$17.5M-$5.5M-$14.0M

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow -$20.4M-$4.2M—
Stock-based compensation $35.6M——
Capital expenditure $500.0K——
Investing cash flow -$500.0K——
Financing cash flow $20.9M$4.2M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001829126-26-004495.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -80M -60M -40M -20M 0 20M Revenue, FY2024: 83K Net income, FY2024: -11.9M Revenue, FY2025: 40K Net income, FY2025: -62.1M FY2023 FY2024 FY2025
Fiscal year FY2023FY2024FY2025
Revenue — $83.0K $40.0K
Gross profit — — —
Net income — -$11.9M -$62.1M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%